BioWorld

Aug. 12, 2009

View Archived Issues

Cracking the IPO Window: Who's After Cumberland?

Cumberland Pharmaceuticals Inc. may not be a traditional biotech, but it's still the first drug company to price an initial public offering since Bioheart Inc.'s measly $5.8 million debut 15 months ago. (BioWorld Today) Read More

Avanir 'Zenvia' Wall Street with Positive Phase III Results in PBA

Read More

Kynapid Stall Narrows Label But Cardiome Forges Ahead

Read More

REMS Question Still Lingers After Fresh D-Mab Risk News

Read More

Chimerix Gets $16.1M to Push Antiviral with Double Potential

Read More

Other News To Note

Read More

Clinic Roundup

Read More